Erlotinib (Tarceva®): A promising drug targeting epidermal growth factor receptor tyrosine kinase

Research output: Contribution to journalReview article

42 Scopus citations

Abstract

Overexpression of the epidermal growth factor receptor (EGFR) is correlated with a poor prognosis in several human malignancies. In addition, cancers overexpressing EGFR respond poorly to both chemotherapy and radiation therapy. Therefore, EGFR is a viable target for cancer therapy. This review will address how EGFR blockade modulates signal transduction, leading to alterations in the cell cycle progression with secondary inhibition of proliferation and differentiation of cancer cells. As a prototypical example, erlotinib (Tarceva®), a reversible EGFR tyrosine kinase inhibitor will be discussed. This drug has demonstrated promising antitumor activity in Phase II trials in several solid tumors and definitive Phase III studies to demonstrate clinical benefit have completed accrual.

Original languageEnglish (US)
Pages (from-to)269-279
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume3
Issue number3
DOIs
Publication statusPublished - Jun 2003

    Fingerprint

Keywords

  • EGFR
  • Erlotinib
  • Phosphorylation
  • Tarceva®
  • Tyrosine kinase

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this